Chief Executive Officer
CurrentResearchers affiliated with the Helmholtz Center for Infection Research (HZI) have developed an unprecedented library of myxobacteria. These bacteria produce small molecules with proven bioactivity. Corallopyronin A, projected for phase I clinical trials in 2026 to treat river blindness and lymphatic filariasis, and epothilone B, the precursor to breast cancer drug Ixabepilone, exemplify the value of the library. MyxoTech is making this library of myxobacterial small molecules available to the pharmaceutical industry. Our company's primary objective is to offer maximum novel chemical diversity for our clients.